← IndicationsOpen filtered programs
Landscape
Sensorineural Hearing Loss
Sensorineural Hearing Loss has 92 tracked records across 34 named organizations, including 13 strong-evidence records and 37 active programs. Records with caveats and trial-derived candidates remain visible for deeper review.
92
Pipeline Records
strong evidence + caveats + candidates
13
Strong Evidence
79 checked records with caveats
37
Active Programs
currently active
1
Marketed / Approved
commercial or approved
34
Organizations
companies, sponsors, and institutions
Competitive Density
100/100
organization breadth + program volume
Pipeline Velocity
33/100
active and late-stage share
Evidence Coverage
14/100
share strong evidence
Completion Signal
17/100
late-stage, approved, or marketed
Attrition Rate
17/100
share discontinued
Concentration
48/100
top-organization share
Programs by Stage
Preclinical9 · 10%
Early Phase 14 · 4%
Phase 19 · 10%
Phase 1/218 · 20%
Phase 221 · 23%
Phase 2/32 · 2%
Phase 310 · 11%
Phase 44 · 4%
Interventional/NA10 · 11%
Approved1 · 1%
Not applicable4 · 4%
Trial / Program Status
Active37 · 40%
Approved1 · 1%
Completed23 · 25%
Discontinued16 · 17%
Paused1 · 1%
Unknown14 · 15%
Modality Breakdown
Small Molecule33 · 36%
Steroid/Anti-inflammatory16 · 17%
Gene Therapy13 · 14%
Biologic8 · 9%
Cell Therapy8 · 9%
Drug Delivery6 · 7%
Regenerative Medicine6 · 7%
RNA Therapy1 · 1%
Small Molecule/Acupoint Injection1 · 1%
Program Types
Therapeutic92 · 100%
Top Organizations
Institution-led study44 · 48%
Investigator-led study5 · 5%
Eli Lilly and Company3 · 3%
Government-led study3 · 3%
Otonomy3 · 3%
Regeneron Pharmaceuticals3 · 3%
Sensorion3 · 3%
Frequency Therapeutics2 · 2%
Population Tags
adult74 · 80%
sensorineural36 · 39%
sudden31 · 34%
pediatric21 · 23%
genetic18 · 20%
tinnitus13 · 14%
congenital11 · 12%
older-adult10 · 11%
age-related9 · 10%
profound9 · 10%
Strong-Evidence Programs
13 recordsOtarmeni by RegeneronStrong evidence
Company: Regeneron Pharmaceuticals · Approved · Approved
Gene TherapyApprovedApproved99% confidence
AK-OTOF by Eli Lilly and AkouosStrong evidence
Company: Eli Lilly and Company · Phase 2 · Active
Gene TherapyPhase 2Active95% confidence
SENS-401 (Arazasetron) by SensorionStrong evidence
Company: Sensorion · Phase 2 · Active
Small MoleculePhase 2Active94% confidence
SENS-501 by SensorionStrong evidence
Company: Sensorion · Phase 1/2 · Active
Gene TherapyPhase 1/2Active94% confidence
Rincell-1 by Rinri TherapeuticsStrong evidence
Company: Rinri Therapeutics · Phase 1/2 · Active
Cell TherapyPhase 1/2Active92% confidence
AC102 by AudioCure PharmaStrong evidence
Company: AudioCure Pharma · Phase 2 · Active
Small MoleculePhase 2Active91% confidence
SPI-1005 by Sound PharmaceuticalsStrong evidence
Company: Sound Pharmaceuticals · Phase 3 · Active
Small MoleculePhase 3Active90% confidence
ACOU085 by Acousia TherapeuticsStrong evidence
Company: Acousia Therapeutics GmbH · Phase 2 · Active
Small MoleculePhase 2Active93% confidence
CIL001 (Paliroden) by CilcareStrong evidence
Company: Cilcare SAS · Phase 1/2 · Active
Small MoleculePhase 1/2Active92% confidence
NS101 by Neuracle ScienceStrong evidence
Company: Neuracle Science Co., Ltd. · Phase 1/2 · Active
BiologicPhase 1/2Active92% confidence
GJB2-GT by SensorionStrong evidence
Company: Sensorion · Preclinical · Active
Gene TherapyPreclinicalActive88% confidence
ReSonance by Lineage Cell TherapeuticsStrong evidence
Company: Lineage Cell Therapeutics · Preclinical · Active
Cell TherapyPreclinicalActive87% confidence
AOK-1Strong evidence
Company: Boehringer Ingelheim · Preclinical · Active
Regenerative MedicinePreclinicalActive82% confidence
Checked Records With Caveats
79 recordsFX-322 by Frequency Therapeutics
Company: Frequency Therapeutics · Phase 2 · Discontinued
Regenerative MedicinePhase 2Discontinued96% confidence
AM-111 by Auris Medical and Altamira
Company: Altamira Therapeutics · Phase 3 · Discontinued
BiologicPhase 3Discontinued95% confidence
FX-345 by Frequency Therapeutics
Company: Frequency Therapeutics · Phase 1 · Discontinued
Regenerative MedicinePhase 1Discontinued95% confidence
OTO-413 by Otonomy
Company: Otonomy · Phase 2 · Discontinued
BiologicPhase 2Discontinued95% confidence
NHPN-1010
Company: Otologic Pharmaceutics · Phase 1 · Completed
Small MoleculePhase 1Completed89% confidence
CGF166 by Novartis
Company: Novartis · Phase 1/2 · Completed
Gene TherapyPhase 1/2Completed89% confidence
OTO-825 by Otonomy
Company: Otonomy · Preclinical · Discontinued
Gene TherapyPreclinicalDiscontinued87% confidence
PIPE-505 by Pipeline Therapeutics
Company: Contineum Therapeutics · Phase 1/2 · Completed
Small MoleculePhase 1/2Completed86% confidence
OTO-6XX by Otonomy
Company: Otonomy · Preclinical · Discontinued
Regenerative MedicinePreclinicalDiscontinued84% confidence
EHT102 by EuHearingStatus caveat
Company: Shanghai EuHearing Therapeutics Co., Ltd · Phase 1/2 · Active
Gene TherapyPhase 1/2Active90% confidence
OTOV101N + OTOV101C by OtoVia TherapeuticsStatus caveat
Company: OtoVia Therapeutics · Interventional/NA · Unknown
Gene TherapyInterventional/NAUnknown86% confidence
Strekin STR001 for Sudden Sensorineural Hearing LossStatus caveat
Company: Strekin AG · Phase 3 · Completed
Small MoleculePhase 3Completed82% confidence
Sun Yat-sen NAD+ Coenzyme I SSNHL StudyStatus caveat
Sponsor / Institution: Institution-led study · Phase 1 · Completed
Small MoleculePhase 1Completed90% confidence
LY3056480 by Audion TherapeuticsStatus caveat
Company: Audion Therapeutics BV · Phase 2 · Discontinued
Small MoleculePhase 2Discontinued88% confidence
Hebei gastrodin acupoint injection SNHL vertigo studyStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Completed
Small Molecule/Acupoint InjectionNot applicableCompleted88% confidence
HG205 RNA base-editing therapy by HuidaGeneStatus caveat
Company: HuidaGene Therapeutics Co., Ltd. · Early Phase 1 · Discontinued
RNA TherapyEarly Phase 1Discontinued88% confidence
MEEI sudden deafness steroid treatment trialStatus caveat
Sponsor / Institution: Institution-led study · Phase 3 · Completed
Steroid/Anti-inflammatoryPhase 3Completed88% confidence
Pamukkale local dexamethasone cochlear implant studyStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Completed
Steroid/Anti-inflammatoryNot applicableCompleted88% confidence
PF-04958242 by Biogen/Pfizer for age-related hearing lossStatus caveat
Company: Biogen · Phase 1 · Completed
Small MoleculePhase 1Completed88% confidence
Fudan oral prednisone acute tinnitus studiesStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Completed
Steroid/Anti-inflammatoryNot applicableCompleted87% confidence